Cellectis S.A. (EPA: ALCLS)
France
· Delayed Price · Currency is EUR
1.780
+0.052 (3.01%)
Nov 19, 2024, 5:15 PM CET
Cellectis Revenue
Cellectis had revenue of $18.05M USD in the quarter ending September 30, 2024, with 997.99% growth. This brings the company's revenue in the last twelve months to $36.04M, up 46.96% year-over-year. In the year 2023, Cellectis had annual revenue of $9.19M, down -64.26%.
Revenue (ttm)
$36.04M
Revenue Growth
+46.96%
P/S Ratio
4.40
Revenue / Employee
$163.09K
Employees
221
Market Cap
173.76M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 48.45B |
EssilorLuxottica Société anonyme | 25.83B |
Sartorius Stedim Biotech S.A. | 2.74B |
bioMérieux S.A. | 3.81B |
Ipsen S.A. | 3.44B |
Eurofins Scientific SE | 6.72B |
Virbac SA | 1.34B |
Ramsay Générale de Santé SA | 5.01B |
Cellectis News
- 15 days ago - Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting - GlobeNewsWire
- 15 days ago - Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 - GlobeNewsWire
- 17 days ago - What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings - GuruFocus
- 21 days ago - Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 - GlobeNewsWire
- 4 weeks ago - Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - GlobeNewsWire
- 2 months ago - Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety - GlobeNewsWire
- 2 months ago - Cellectis: Cheap With Promising But Speculative Cancer Therapies - Seeking Alpha